Oncternal Therapeutics Inc
NASDAQ:ONCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
US |
|
C
|
CBI Co Ltd
KOSDAQ:013720
|
KR |
|
1300 Smiles Ltd
ASX:ONT
|
AU |
|
C
|
Comintel Corporation Bhd
KLSE:COMCORP
|
MY |
|
K
|
Korea Information Certificate Authority Inc
KOSDAQ:053300
|
KR |
|
S
|
SolarBank Corp
CNSX:SUNN
|
CA |
|
Ashika Credit Capital Ltd
BSE:543766
|
IN |
|
Invibes Advertising NV
PAR:ALINV
|
BE |
|
Sparx Group Co Ltd
TSE:8739
|
JP |
|
Akka Technologies SE
F:AF5
|
BE |
|
Uni-Asia Group Ltd
SGX:CHJ
|
HK |
|
Value Partners Group Ltd
HKEX:806
|
HK |
|
Del Monte Pacific Ltd
SGX:D03
|
SG |
|
Delta 9 Cannabis Inc
TSX:DN
|
CA |
|
I
|
Ilyda SA
ATHEX:ILYDA
|
GR |
|
T
|
Trisula Textile Industries Tbk PT
IDX:BELL
|
ID |
|
Amkor Technology Inc
NASDAQ:AMKR
|
US |
|
Malteries Franco Belges SA
PAR:MALT
|
FR |
|
I
|
IMS SA
WSE:IMS
|
PL |
|
Xining Special Steel Co Ltd
SSE:600117
|
CN |
|
Henan Lantian Gas Co Ltd
SSE:605368
|
CN |
|
Element 25 Ltd
ASX:E25
|
AU |
|
Genesis Land Development Corp
TSX:GDC
|
CA |
|
Prosus NV
OTC:PROSF
|
NL |
Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
